Also found in: Acronyms.


The Consortium to Establish a Registry for Alzheimer's Disease. A neurological testing instrument used to assess patients with Alzheimer’s disease.

Verbal fluency test; Boston Naming Test; MMSE; 10-item word recall; constructional praxis; delayed recall of praxis items.

Time required
20–30 minutes.

Convenient and effective at assessing and tracking cognitive decline.
References in periodicals archive ?
Which of the following statements is true of the CERAD criteria?
CERAD criteria for AD Plaque Frequency Age None Sparse Moderate Frequent <50 0 C C C 50-75 0 B C C >75 0 A B C No evidence of AD: 0 Possible AD: A plus dementia or B/C and no dementia Probable AD: B plus dementia Definite AD: C plus dementia Example: A 60-year-old man with a clinical history of dementia has moderate numbers (approximately 6-100X field) of senile plaques at autopsy.
Participants' performances on the CERAD neuropsychological battery are presented in Table 2.
Table 2 Participants' Raw and (z) Scores on CERAD Neuropsychological Tests MMSE Fluency BNT Participants with AD AD23 10 (-8.
CERAD plan to upgrade four laboratories and, in that connection, replace fixtures in them.
The main outcome of interest was clinical impairment, defined as impaired cognition indicated by failing scores on the CERAD or the TICS-M.
They demonstrated more impairment of language on the Category Fluency Test and the Mini-Boston Naming Test, performed worse on three-dimensional construction tasks, and their CERAD (Consortium to Establish a Registry for Alzheimer's Disease) scores also showed greater memory impairment.
For the ROS and Rush MAP studies, the CERAD criteria were modified to be implemented without adjustment for age or knowledge of the clinical diagnosis.
Among the ROS and Rush MAP patients diagnosed with probable AD, 93% (95 patients) were confirmed by pathologic examination using the CERAD criteria, as were 93% (273) of the clinic patients with clinically probable AD.
Progression of Alzheimer's disease in black and white patients: the CERAD experience, part XVI.
In those with no stroke, AD pathology could be relatively severe (up to a CERAD score of 2) and still have a relatively low risk of dementia.